Generic Medicine Info
May be taken with or without food. Swallow whole, do not chew/crush.
Hepatic impairment, severe renal impairment, uncontrolled HTN or narrow-angle glaucoma. Concomitant use w/ MAOIs or w/in 14 days of discontinuing the MAOI. Use w/ linezolid or IV methylene blue. Concomitant use w/ potent CYP1A2 inhibitors (e.g. ciprofloxacin, enoxacin).
Special Precautions
Patient w/ HTN, gastroparesis, mania or hypomania, increased intraocular pressure or at risk of acute narrow-angle glaucoma, seizure, bleeding disorders, mild to moderate renal impairment. Smokers. Gradual dose reduction is recommended rather than abrupt withdrawal. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor BP and mental status for depression. Closely observe for clinical worsening, suicidality and unusual changes in behaviour.
Adverse Reactions
Changes in behaviour, suicidal ideation, HTN, headache, somnolence, fatigue, dizziness, insomnia, agitation, tremor, anxiety, insomnia, lethargy, abnormal dreams, nausea, xerostomia, palpitation, hyperhydrosis, decreased libido, hot flushes, sexual dysfunction, vomiting, constipation, diarrhoea, dyspepsia, abdominal pain, wt gain, decreased appetite, erectile dysfunction, increased hepatic enzymes, muscle spasms, paraesthesia, tinnitus, blurred vision, mydriasis, nasopharyngitis, hyponatraemia, may impair platelet aggregation. Stevens-Johnson syndrome and erythema multiforme.
Potentially Fatal: Hepatic failure w/ or w/o jaundice.
Drug Interactions
Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants.
CIMS Class
Antidepressants / Drugs For Neuropathic Pain
ATC Classification
N06AX21 - duloxetine ; Belongs to the class of other antidepressants.
Disclaimer: This information is independently developed by CIMS based on duloxetine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in